GlucoTrack announces USPTO approval for issuance of patents for CBGM platform

Glucotrack (GCTK) announced that the US Patent and Trademark Office, USPTO, has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company’s continuous blood glucose monitoring, CBGM, platform. The patents strengthen Glucotrack’s competitive position and intellectual property protection as the Company advances its multi-year, fully implantable CBGM system toward commercialization. “These patents represent a significant milestone in protecting our innovative technology that is at the core of our CBGM system,” said Paul Goode, PhD, President and Chief Executive Officer of Glucotrack. “Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization. These patents establish important competitive barriers and strengthen our position to deliver a differentiated approach to diabetes management.”